What is the first line of treatment for a patient presenting with onychomycosis (fingernail fungus)?

First-Line Treatment for Fingernail Fungus (Onychomycosis)

Oral terbinafine 250 mg once daily for 6 weeks is the first-line treatment for fingernail onychomycosis caused by dermatophytes, achieving cure rates of 80-90%. 1, 2

Critical First Step: Confirm the Diagnosis

Never initiate treatment without mycological confirmation through KOH preparation, fungal culture, or nail biopsy—this is the most common cause of treatment failure. 2, 3

• Dermatophytes (primarily Trichophyton rubrum) cause 90-95% of cases 4
• Candida and non-dermatophyte molds require different treatment approaches 2

Treatment Algorithm by Causative Organism

For Dermatophyte Onychomycosis (Most Cases)

Terbinafine is superior to all other oral antifungals for dermatophyte infections, both in vitro and in vivo. 2

• Dosing: 250 mg once daily for 6 weeks for fingernails 1, 3
• Efficacy: 80-90% mycological cure rate for fingernails 1, 2
• Advantages: Shorter treatment duration, fewer drug interactions, and superior efficacy compared to itraconazole 2, 5

Alternative: Itraconazole if terbinafine is contraindicated or not tolerated 1

• Continuous dosing: 200 mg daily for 12 weeks 1
• Pulse therapy: 400 mg daily for 1 week per month for 2 pulses (fingernails) 1
• Take with food and acidic pH for optimal absorption 1

For Candida Onychomycosis

Itraconazole is the most effective agent when Candida invades the nail plate. 2

• Dosing: 400 mg daily for 1 week per month, repeated for 2 months for fingernails 2
• Azoles are specifically superior for yeast infections 2

Pre-Treatment Monitoring Requirements

Obtain baseline liver function tests (ALT and AST) and complete blood count before starting terbinafine, especially in patients with history of liver disease, excessive alcohol use, or hepatitis. 1, 3

• Hepatotoxicity can occur even without pre-existing liver disease 3
• Cases of liver failure requiring transplant or resulting in death have been reported 3

Common Adverse Effects to Counsel Patients About

Terbinafine: 1, 3

• Headache and gastrointestinal upset (most common)
• Taste disturbance or loss (can be severe and permanent)
• Smell disturbance or loss (may be permanent)
• Can aggravate psoriasis or cause subacute lupus-like syndrome

Itraconazole: 1

• Headache and gastrointestinal upset
• Contraindicated in heart failure
• Multiple drug interactions via CYP3A4 inhibition 4

When to Consider Topical Therapy Instead

Topical therapy is inferior to systemic treatment except in very limited cases. 1, 2

Consider topical agents only for: 1, 6

• Superficial white onychomycosis (SWO)
• Very early distal lateral subungual onychomycosis (DLSO)
• Mild to moderate infection without lunula involvement
• When systemic therapy is contraindicated

Topical options: 1

• Amorolfine 5% lacquer: once or twice weekly for 6-12 months
• Ciclopirox 8% lacquer: once daily for up to 48 weeks (mycological cure rates only 5.5-8.5%) 6

Special Population Considerations

Diabetic Patients

Terbinafine is the agent of choice due to low risk of drug interactions and no hypoglycemia risk. 2

• Onychomycosis significantly predicts foot ulcers and cellulitis in diabetics 2

Immunocompromised Patients

Prefer terbinafine over itraconazole due to lower risk of interactions with antiretrovirals and immunosuppressive medications. 2

Pediatric Patients (Age 1-12 Years)

Both terbinafine and itraconazole are first-line options with higher cure rates than adults. 1, 2

• Terbinafine dosing: 62.5 mg/day (<20 kg), 125 mg/day (20-40 kg), 250 mg/day (>40 kg) for 6 weeks 1, 2

Setting Realistic Expectations

Mycological cure rates are approximately 30% higher than clinical cure rates. 1

• Optimal clinical effect occurs months after treatment completion due to slow nail growth 3
• Complete nail regrowth may take up to 18 months 7
• Nails may not return to completely normal appearance if pre-existing dystrophy was present 1, 2
• Re-evaluate patients 3-6 months after initiating treatment 2

Managing Treatment Failure (20-30% of Cases)

Common causes: 2, 7

• Poor adherence to treatment
• Poor drug absorption
• Immunosuppression
• Dermatophyte resistance
• Dermatophytoma (compact fungal mass preventing drug penetration)

If treatment fails: 2, 7

• Consider partial nail removal for dermatophytoma
• Switch to alternative agent (terbinafine to itraconazole or vice versa)

Prevention of Recurrence (25% Relapse Rate)

Always wear protective footwear in communal bathing facilities, gyms, and hotel rooms to avoid re-exposure to T. rubrum. 1, 2, 8

Additional preventive measures: 1, 2, 7

• Apply absorbent antifungal powders to shoes and feet
• Wear cotton, absorbent socks
• Keep nails as short as possible
• Avoid sharing toenail clippers
• Discard old, heavily contaminated footwear or treat with antifungal solutions
• Treat all infected family members simultaneously

Critical Pitfalls to Avoid

• Do not treat based on clinical appearance alone—incorrect diagnosis is the most common cause of treatment failure 2
• Do not use concomitant systemic and topical antifungals—no studies support this combination 6
• Warn patients to immediately report persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools and discontinue terbinafine 3
• Monitor for drug interactions with terbinafine (CYP2D6 inhibitor) in patients taking tricyclic antidepressants, SSRIs, atypical antipsychotics, beta blockers, or tamoxifen 4, 8